www.biopharmadive.com Open in urlscan Pro
2606:4700:4400::ac40:91e0 Public Scan

Back to summary

URL:
https://www.biopharmadive.com/editors/dalvarado/
Submission Tags: @phish_report
Submission: On November 26 via api (November 26th 2024, 11:01:22 pm UTC) from FI — Scanned from FI

Form analysis
6 forms found in the DOM

Name: signup-inter-form — POST /signup/

<form id="signup-inter-form" class="form-basic" name="signup-inter-form" action="/signup/" method="POST">
  <input type="hidden" name="signup_box_location" value="interstitial">
  <input type="hidden" name="signup_initial_url_path" value="">
  <h1> Don’t miss tomorrow’s biopharma industry news </h1>
  <p class="interstitial-text"> Let BioPharma Dive’s free newsletter keep you informed, straight from your inbox. </p>
  <p class="form-error__message" id="interstitial-error"></p>
  <div id="form-interstitial">
    <input type="email" name="email" placeholder="Work email address" class="email" required="" id="id_d01c12_email">
    <div id="newsletter-list-section">
      <ul id="id_d01c12_site_newsletters" class="list-no-bullets">
        <li><label for="id_d01c12_site_newsletters_0"><input type="checkbox" name="site_newsletters" value="20" class="list-no-bullets" id="id_d01c12_site_newsletters_0"> Daily Dive <span class="secondary-label">M-F</span></label>
        </li>
        <li><label for="id_d01c12_site_newsletters_1"><input type="checkbox" name="site_newsletters" value="42" class="list-no-bullets" id="id_d01c12_site_newsletters_1"> Commercialization Weekly <span class="secondary-label">Every
              Wednesday</span></label>
        </li>
        <li><label for="id_d01c12_site_newsletters_2"><input type="checkbox" name="site_newsletters" value="43" class="list-no-bullets" id="id_d01c12_site_newsletters_2"> Gene Therapy Weekly <span class="secondary-label">Every Thursday</span></label>
        </li>
        <li><label for="id_d01c12_site_newsletters_3"><input type="checkbox" name="site_newsletters" value="2934" class="list-no-bullets" id="id_d01c12_site_newsletters_3"> Emerging Biotech Weekly <span class="secondary-label">Every
              Tuesday</span></label>
        </li>
      </ul>
    </div>
    <div id="interstitial-consent-container">
      <input name="user_consent" value="1" id="id_user_consent" type="checkbox">
      <span> By signing up to receive our newsletter, you agree to our <a href="https://www.industrydive.com/terms-of-use/" target="_blank">Terms of Use</a> and
        <a href="https://www.industrydive.com/privacy-policy/" target="_blank">Privacy Policy</a>. You can unsubscribe at anytime. </span>
    </div>
  </div>
  <input id="signup-inter-submit" class="email_submit submit button" type="submit" data-role="none" value="Subscribe today">
</form>

GET /search/

<form action="/search/" method="GET" data-ajax="false">
  <label for="search-desktop">
    <span class="screen-reader-text search">Search</span>
  </label>
  <input id="search-desktop" type="search" name="q" placeholder="Search" data-role="none">
  <button type="submit" value="" data-role="none" class="search-button-front analytics t-search-navigation-drawer">
    <img src="/static/img/menu_icons/search.svg?320116291121" alt="search" height="16" width="16" loading="lazy">
  </button>
  <img class="close" src="/static/img/menu_icons/close.svg?273117231121" width="16" height="16" alt="close search" loading="lazy">
</form>

.

<form action="." id="article-list-form">
  <input type="hidden" name="month_filter_value" value="">
  <input type="hidden" name="scroll-top" value="">
</form>

Name: signup — POST /signup/

<form class="form js-form-email-validate" name="signup" action="/signup/" method="POST">
  <label for="id_463255_email" class="email-input js-email-input">
    <span class="screen-reader-text">Email:</span>
    <input type="email" name="email" placeholder="Work email address" class="email" required="" id="id_463255_email">
  </label>
  <input type="hidden" name="signup_box_location" value="sidebar">
  <input type="hidden" name="signup_initial_url_path" value="/editors/dalvarado/">
  <input type="hidden" name="js_enabled" value="1" id="id_463255_js_enabled">
  <ul class="signup-list list-no-bullets">
    <li>
      <label><span class="screen-reader-text">Select Newsletter:</span></label>
      <input id="newsletter-sidebar-checkbox-20" type="checkbox" name="site_newsletters" value="20" class="checkbox">
      <label for="newsletter-sidebar-checkbox-20">
        <span class="newsletter-title">Daily Dive</span>
        <span class="secondary-label">M-F</span>
      </label>
    </li>
    <li>
      <label><span class="screen-reader-text">Select Newsletter:</span></label>
      <input id="newsletter-sidebar-checkbox-42" type="checkbox" name="site_newsletters" value="42" class="checkbox">
      <label for="newsletter-sidebar-checkbox-42">
        <span class="newsletter-title">Commercialization Weekly</span>
        <span class="secondary-label">Every Wednesday</span>
      </label>
    </li>
    <li>
      <label><span class="screen-reader-text">Select Newsletter:</span></label>
      <input id="newsletter-sidebar-checkbox-43" type="checkbox" name="site_newsletters" value="43" class="checkbox">
      <label for="newsletter-sidebar-checkbox-43">
        <span class="newsletter-title">Gene Therapy Weekly</span>
        <span class="secondary-label">Every Thursday</span>
      </label>
    </li>
    <li>
      <label><span class="screen-reader-text">Select Newsletter:</span></label>
      <input id="newsletter-sidebar-checkbox-2934" type="checkbox" name="site_newsletters" value="2934" class="checkbox">
      <label for="newsletter-sidebar-checkbox-2934">
        <span class="newsletter-title">Emerging Biotech Weekly</span>
        <span class="secondary-label">Every Tuesday</span>
      </label>
    </li>
    <li>
      <label><span class="screen-reader-text">Select user consent:</span></label>
      <input type="checkbox" name="user_consent" id="id_user_consent-sidebar" value="1" class="checkbox">
      <label for="id_user_consent-sidebar">
        <span class="signup-user-consent_box">
          <span> By signing up to receive our newsletter, you agree to our <a href="https://www.industrydive.com/terms-of-use/" target="_blank">Terms of Use</a> and
            <a href="https://www.industrydive.com/privacy-policy/" target="_blank">Privacy Policy</a>. You can unsubscribe at anytime. </span>
        </span>
      </label>
    </li>
  </ul>
  <button class="button button--medium signup-button" type="submit" value="Sign up">Sign up</button>
  <script type="module" src="/static/js/dist/sendEmailToLytics.bundle.js?081516261124"></script>
  <label class="error email_error" style="display:none;">A valid email address is required.</label>
  <label class="error newsletter-error" style="display:none;">Please select at least one newsletter.</label>
</form>

GET /search/

<form action="/search/" method="GET" data-ajax="false">
  <label for="search-mobile">
    <span class="screen-reader-text">Search</span>
    <input id="search-mobile" type="search" name="q" placeholder="Search" data-role="none">
  </label>
  <button type="submit" value="" data-role="none" class="search-button-front analytics t-search-navigation-mobile">
    <img src="/static/img/menu_icons/search.svg?320116291121" width="15" height="15" alt="search">
  </button>
</form>

Name: signup — POST /signup/

<form class="form js-form-email-validate" name="signup" action="/signup/" method="POST">
  <label for="id_256b09_email" class="email-input js-email-input">
    <span class="screen-reader-text">Email:</span>
    <input type="email" name="email" placeholder="Work email address" class="email" required="" id="id_256b09_email">
  </label>
  <input type="hidden" name="signup_box_location" value="integrated_menu">
  <input type="hidden" name="signup_initial_url_path" value="/editors/dalvarado/">
  <input type="hidden" name="js_enabled" value="1" id="id_256b09_js_enabled">
  <ul class="signup-list list-no-bullets">
    <li>
      <label><span class="screen-reader-text">Select Newsletter:</span></label>
      <input id="newsletter-integrated_menu-checkbox-20" type="checkbox" name="site_newsletters" value="20" class="checkbox">
      <label for="newsletter-integrated_menu-checkbox-20">
        <span class="newsletter-title">Daily Dive</span>
        <span class="secondary-label">M-F</span>
      </label>
    </li>
    <li>
      <label><span class="screen-reader-text">Select Newsletter:</span></label>
      <input id="newsletter-integrated_menu-checkbox-42" type="checkbox" name="site_newsletters" value="42" class="checkbox">
      <label for="newsletter-integrated_menu-checkbox-42">
        <span class="newsletter-title">Commercialization Weekly</span>
        <span class="secondary-label">Every Wednesday</span>
      </label>
    </li>
    <li>
      <label><span class="screen-reader-text">Select Newsletter:</span></label>
      <input id="newsletter-integrated_menu-checkbox-43" type="checkbox" name="site_newsletters" value="43" class="checkbox">
      <label for="newsletter-integrated_menu-checkbox-43">
        <span class="newsletter-title">Gene Therapy Weekly</span>
        <span class="secondary-label">Every Thursday</span>
      </label>
    </li>
    <li>
      <label><span class="screen-reader-text">Select Newsletter:</span></label>
      <input id="newsletter-integrated_menu-checkbox-2934" type="checkbox" name="site_newsletters" value="2934" class="checkbox">
      <label for="newsletter-integrated_menu-checkbox-2934">
        <span class="newsletter-title">Emerging Biotech Weekly</span>
        <span class="secondary-label">Every Tuesday</span>
      </label>
    </li>
    <li>
      <label><span class="screen-reader-text">Select user consent:</span></label>
      <input type="checkbox" name="user_consent" id="id_user_consent-integrated_menu" value="1" class="checkbox">
      <label for="id_user_consent-integrated_menu">
        <span class="signup-user-consent_box">
          <span> By signing up to receive our newsletter, you agree to our <a href="https://www.industrydive.com/terms-of-use/" target="_blank">Terms of Use</a> and
            <a href="https://www.industrydive.com/privacy-policy/" target="_blank">Privacy Policy</a>. You can unsubscribe at anytime. </span>
        </span>
      </label>
    </li>
  </ul>
  <button class="button button--medium signup-button" type="submit" value="Sign up">Sign up</button>
  <script type="module" src="/static/js/dist/sendEmailToLytics.bundle.js?081516261124"></script>
  <label class="error email_error" style="display:none;">A valid email address is required.</label>
  <label class="error newsletter-error" style="display:none;">Please select at least one newsletter.</label>
</form>

Text Content

CONTINUE TO SITE ➞

DON’T MISS TOMORROW’S BIOPHARMA INDUSTRY NEWS

Let BioPharma Dive’s free newsletter keep you informed, straight from your
inbox.

* Daily Dive M-F
* Commercialization Weekly Every Wednesday
* Gene Therapy Weekly Every Thursday
* Emerging Biotech Weekly Every Tuesday

By signing up to receive our newsletter, you agree to our Terms of Use and
Privacy Policy. You can unsubscribe at anytime.

* Deep Dive
* Library
* Events
* Press Releases
* Topics

Search
* Pharma
* Biotech
* FDA
* Clinical Trials
* Deals
* Drug Pricing
* Gene Therapy

← Editorial Team

DELILAH ALVARADO

Staff Reporter

Delilah is a staff reporter for BioPharma Dive. Before Industry Dive she covered
business tech and startup news and has reported on social issues, politics and
culture. She has a B.S. from Texas State University and is obsessed with dogs
and horror films.

GET IN TOUCH

Email dalvarado@industrydive.com
Submit a tip to our team

--------------------------------------------------------------------------------

342 ARTICLES BY DELILAH ALVARADO

Filter by month: Show All
2024NovemberOctoberSeptemberAugustJulyJuneMayAprilMarchFebruaryJanuary2023DecemberNovemberOctoberSeptemberAugustJulyJuneMayAprilMarchFebruaryJanuary2022DecemberNovemberOctoberSeptemberAugustJulyJune

* SYNDAX SECURES FDA OK FOR NEW KIND OF LEUKEMIA DRUG

Nov. 18, 2024

* SURVIVING IN BIOTECH’S NEW NORMAL: 5 TIPS FROM INDUSTRY VCS AND CEOS

Nov. 15, 2024

* FDA LIFTS PAUSE ON NOVAVAX FLU VACCINE TRIALS

Nov. 11, 2024

* KALARIS TO GO PUBLIC VIA REVERSE MERGER WITH ALLOVIR

Nov. 8, 2024

* NEUROGENE SECURES $200M AHEAD OF ANTICIPATED STUDY READOUT

Nov. 4, 2024

* GSK VACCINE SALES SINK ON LOWER DEMAND FOR RSV, SHINGLES SHOTS

Oct. 30, 2024

* PFIZER SALES OF RSV VACCINE EBB, BUT COMPANY GAINS MARKET SHARE

Oct. 29, 2024

* SANOFI EARNINGS BOOSTED BY BEYFORTUS, EARLIER VACCINE SALES

Oct. 25, 2024

* MERCK, PFIZER LIFTED AS CDC BACKS BROADER USE OF PNEUMOCOCCAL VACCINES

Oct. 24, 2024

* PFIZER’S RSV VACCINE CLEARED BY FDA FOR USE IN SOME YOUNGER ADULTS

Oct. 23, 2024

* SANOFI MOVES AHEAD WITH CD&R DEAL FOR STAKE IN CONSUMER BUSINESS

Oct. 21, 2024

* MERCK ANTIBODY REDUCES RSV-RELATED DISEASE, HOSPITALIZATIONS IN TRIAL

Oct. 18, 2024

* SAGE TO CUT ONE-THIRD OF WORKFORCE, STREAMLINE DRUG PIPELINE

Oct. 17, 2024

* FDA PUTS NOVAVAX FLU VACCINE TRIALS ON HOLD

Oct. 16, 2024

* FORBION FOLLOWS STRING OF STARTUP EXITS WITH $2.2B FUNDRAISE

Oct. 15, 2024

* GSK SAYS ANTIBODY DRUG SUCCEEDS IN TESTING FOR CHRONIC NASAL CONDITION

Oct. 14, 2024

* PURESPRING RAISES $105M TO ADVANCE GENE THERAPY FOR KIDNEY DISEASE

Oct. 9, 2024

* GSK SAYS RSV VACCINE PROTECTS AGAINST DISEASE OVER THREE SEASONS

Oct. 8, 2024

* GSK’S VIIV TO EXPAND SUPPLY OF HIV DRUG IN AFRICA

Oct. 7, 2024

* EDITAS TRADES VERTEX FEES FOR UPFRONT CASH IN DRI DEAL

Oct. 4, 2024

* GILEAD AGREES TO LICENSE NEW HIV DRUG IN LOW-INCOME COUNTRIES

Oct. 2, 2024

* AKTIS RAISES $175M TO FUEL RADIOPHARMA DRUG DEVELOPMENT

Sept. 30, 2024

* BLUEBIRD TO LAY OFF ANOTHER 25% OF WORKFORCE IN LATEST RESTRUCTURING

Sept. 24, 2024

* STARTUP VICEBIO BANKS $100M IN BID TO MAKE ‘COST-EFFECTIVE’ VACCINES

Sept. 23, 2024

* ROCHE’S XOFLUZA REDUCES FLU TRANSMISSION IN PHASE 3 STUDY

Sept. 19, 2024

* SANOFI READIES TO MEET US DEMAND FOR RSV ANTIBODY

Sept. 16, 2024

* MODERNA, TRAILING RIVALS, CHECKS ITS RSV SHOT EXPECTATIONS

Sept. 13, 2024

* F2G RAISES $100M TO BRING ANTIFUNGAL DRUG BACK TO FDA

Sept. 12, 2024

* BAIN CLOSES $3B BIOTECH FUND AMID FLURRY OF STARTUP BUYOUTS

Sept. 10, 2024

* BIOMARIN, HAVING RETRENCHED, OUTLINES PLANS FOR GROWTH

Sept. 4, 2024

* VAXCYTE’S “BEST-CASE” DATA FOR PNEUMOCOCCAL VACCINE BOOST SHARES

Sept. 3, 2024

* BIOMARIN TO LAY OFF OVER 200 EMPLOYEES

Aug. 29, 2024

* BAYER PARTNERS WITH RNA DRUGMAKER TO DEVELOP NEW CANCER THERAPIES

Aug. 28, 2024

* PFIZER LAUNCHES DTC SERVICE FOR MIGRAINE, COVID DRUGS

Aug. 27, 2024

* TOME BIOSCIENCES TO LAY OFF OVER 100 EMPLOYEES

Aug. 26, 2024

* PFIZER, BIONTECH STUMBLE IN EFFORT TO DEVELOP COMBINATION FLU, COVID SHOT

Aug. 16, 2024

* PFIZER BUILDS CASE FOR RSV SHOT WITH DATA FROM IMMUNOCOMPROMISED ADULTS

Aug. 12, 2024

* ZEPBOUND SHORTAGES EASE, BUT LILLY CAUTIONS PHARMACY AVAILABILITY MAY REMAIN
‘CHOPPY’

Aug. 8, 2024

* BIOTECH ENTREPRENEUR ARIE BELLDEGRUN LAUNCHES NEW ‘SCIENCE-FIRST’ CREDIT FIRM

Aug. 6, 2024

* BIOTECH RED QUEEN LAUNCHES WITH $55M TO BUILD VERSATILE ANTIVIRALS

Aug. 6, 2024

* UNIQURE RESTRUCTURING TO CLAIM 300 JOBS

Aug. 1, 2024

* MODERNA SHARES FALL AMID LOWER SALES OUTLOOK FOR RSV, COVID SHOTS

Aug. 1, 2024

* J&J SEEKS EXPANDED APPROVAL FOR ANTIDEPRESSANT SPRAVATO

July 22, 2024

* NGM, NOW PRIVATE, RAISES $122M FOR REDRAWN RESEARCH PLANS

July 17, 2024

* HILLEVAX’S NOROVIRUS VACCINE INEFFECTIVE IN LARGE TRIAL OF INFANTS

July 8, 2024

* MODERNA GETS US FUNDING FOR BIRD FLU VACCINE DEVELOPMENT

July 2, 2024

* ELI LILLY INKS ANOTHER RADIOPHARMA DEAL, GAINING OPTION TO BUY STARTUP

July 1, 2024

* MERCK’S PNEUMOCOCCAL VACCINE GETS CDC PANEL BACKING

June 28, 2024

* RSV VACCINE MAKERS’ SHARES FALL AS CDC ADJUSTS SHOT GUIDANCE

June 27, 2024

* WOMEN WITH A COMMON HORMONAL DISORDER HAVE FEW GOOD TREATMENT OPTIONS. COULD
GLP-1 DRUGS HELP?

June 26, 2024

* MERCK WINS FDA OK FOR VACCINE RIVAL TO PFIZER’S PNEUMOCOCCAL SHOT

June 18, 2024

* ABORTION PILL RULING OFFERS MEASURE OF RELIEF FOR FDA, BIOTECH

June 17, 2024

* SUPREME COURT PRESERVES ACCESS TO ABORTION PILL IN UNANIMOUS RULING

June 13, 2024

* FLAGSHIP TAPS STARTUP TO HUNT FOR OBESITY DRUGS THAT MIGHT INTEREST PFIZER

June 12, 2024

* MODERNA SAYS COMBINATION FLU, COVID SHOT SUCCEEDS IN STUDY

June 10, 2024

* GSK ACQUIRES OLIGONUCLEOTIDE DRUG STARTUP ELSIE

June 6, 2024

* FDA ADVISERS BACK UPDATING COVID SHOTS TO TARGET JN.1 VIRUS FAMILY

June 6, 2024

* STRUCTURE PILL LEADS TO COMPETITIVE WEIGHT LOSS IN OBESITY STUDY

June 3, 2024

* MODERNA WINS FDA APPROVAL FOR RSV VACCINE

May 31, 2024

* A BIOTECH WORKING ON A NEW APPROACH TO IVF RAISES $33M IN FRESH FUNDING

May 29, 2024

* AGIOS CASHES IN ON CANCER DRUG AGAIN WITH $905M ROYALTY PHARMA DEAL

May 28, 2024

* CERTAIN MENOPAUSAL HORMONE THERAPY COULD RAISE OVARIAN CANCER RISK, STUDY
FINDS

May 23, 2024

* LILLY PARTNERS WITH AKTIS, DEEPENING RADIOPHARMA INVESTMENT

May 21, 2024

* DETAILED TRIAL DATA SHOW BAYER DRUG ALLEVIATES MENOPAUSE SYMPTOMS

May 16, 2024

* BOLT BIOTHERAPEUTICS TO LAY OFF STAFF, ABANDON LEAD ADC CANDIDATE

May 15, 2024

* BAYER DETAILS LAYOFFS AS COMPANY SHAKE-UP CONTINUES

May 14, 2024

* FDA DELAYS DECISION ON MODERNA RSV VACCINE

May 10, 2024

* ASTRAZENECA WITHDRAWS COVID-19 VACCINE, CITING DECLINING DEMAND

May 8, 2024

* NOVARTIS TO BUY MARIANA ONCOLOGY IN RADIOPHARMACEUTICAL EXPANSION

May 2, 2024

* GSK RAISES FORECASTS ON STRONG VACCINE, HIV DRUG SALES

May 1, 2024

* BIOGEN SEES ‘ENCOURAGING’ TRENDS FOR POSTPARTUM DEPRESSION DRUG

April 24, 2024

* FORMER BRISTOL MYERS CEO TAPPED AS NOVARTIS’ NEXT BOARD CHAIR

April 23, 2024

* LILLY TO BUY INJECTABLE DRUG PLANT IN MANUFACTURING RAMP-UP

April 22, 2024

* IPSEN, SKYHAWK TO DEVELOP RNA-TARGETING PILLS FOR RARE BRAIN DISEASES

April 22, 2024

* REGENERON COMMITS $500M TO NEW VENTURE CAPITAL FUND

April 15, 2024

* CENTURY BUYS A STARTUP, RAISES FUNDING IN CELL THERAPY EXPANSION

April 11, 2024

* J&J, RALLYBIO PARTNER ON DRUG DEVELOPMENT FOR RARE FETAL CONDITION

April 10, 2024

* NEW POSTPARTUM DEPRESSION DRUGS ARE HERE. DIAGNOSIS, TREATMENT HURDLES STILL
STAND IN THE WAY.

April 10, 2024

* PFIZER, WITH NEW STUDY RESULTS, SEEKS TO BRING RSV SHOT TO ADULTS AGED 18-59

April 9, 2024

* BOEHRINGER INGELHEIM TO LAY OFF STAFF AMID BIOSIMILAR CHALLENGES

April 5, 2024

* ROIVANT REVEALS POSITIVE IMMUNE DRUG DATA, SHARE BUYBACK PLANS

April 2, 2024

* VERTEX MOVES KIDNEY DISEASE DRUG INTO LATE-STAGE TESTING

April 1, 2024

* MODERNA GETS BLACKSTONE BACKING FOR FLU VACCINE R&D

March 27, 2024

* SUPREME COURT WEIGHS ABORTION OPPONENTS’ STANDING IN MIFEPRISTONE CASE

March 26, 2024

* ABBVIE TO BUY IMMUNE DRUG DEVELOPER LANDOS

March 25, 2024

* NEXTCURE TO LAY OFF 37% OF STAFF, DIAL BACK RESEARCH PLANS

March 21, 2024

* WITH NEW DATA, BAYER READIES RIVAL TO ASTELLAS MENOPAUSE DRUG

March 19, 2024

* BLUEBIRD, SHORT ON CASH, TAKES ON $175M IN DEBT FINANCING

March 18, 2024

* MERCK REVEALS PLANS TO DEVELOP NEWER HPV SHOTS

March 13, 2024

* BOEHRINGER, SOSEI HEPTARES TEAM UP IN SCHIZOPHRENIA DRUG DEAL

March 11, 2024

* ALUMIS, TAKING AIM AT BRISTOL MYERS, PULLS IN $259M FOR TYK2 DRUG WORK

March 6, 2024

* CVS, WALGREENS TO START SELLING ABORTION PILL IN SOME STATES

March 4, 2024

* CDC PANEL MULLS CHANGES TO RSV VACCINE RECOMMENDATION

March 1, 2024

* WOMEN’S HEALTH COMPANY OBSEVA TO WIND DOWN, LAY OFF STAFF

Feb. 28, 2024

* DENALI, FRESH OFF STUDY SETBACK, GETS $500M LIFT

Feb. 27, 2024

* GSK DRUG MEETS GOAL IN LATE-STAGE GONORRHEA STUDY

Feb. 26, 2024

* BIDEN ADMINISTRATION PLEDGES $100M TOWARD WOMEN’S HEALTH RESEARCH

Feb. 22, 2024

* VIR, IN MIDST OF RESTRUCTURING, LOSES ITS CHIEF MEDICAL OFFICER

Feb. 21, 2024

* FDA PUTS HOLD ON RAPT TRIALS OF DRUG FOR ECZEMA, ASTHMA

Feb. 20, 2024

* ALS DRUG FROM DENALI, SANOFI FALLS SHORT IN MID-STAGE STUDY

Feb. 16, 2024

* LIANBIO TO SHUT DOWN, RETURN CASH TO INVESTORS

Feb. 14, 2024

* ALYS LAUNCHES WITH $100M AND A PIPELINE OF SKIN DISEASE DRUGS

Feb. 12, 2024

* BRIDGEBIO SELLS PARTIAL RIGHTS TO DWARFISM DRUG FOR $100M

Feb. 7, 2024

* VALNEVA SELLS REGULATORY ‘FAST PASS’ FOR $103M

Feb. 5, 2024

* SANOFI APPOINTS NESTLÉ EXECUTIVE AS NEW FINANCE CHIEF

Feb. 1, 2024

* GSK SALES OF RSV VACCINE STAY STRONG, BEATING FORECAST

Jan. 31, 2024

* AT FDA MEETING, EXPERTS WRESTLE WITH HURDLES TO DEVELOPING PRETERM BIRTH
DRUGS

Jan. 25, 2024

* COHERUS SELLS LUCENTIS BIOSIMILAR TO SANDOZ FOR $170M

Jan. 22, 2024

* IKENA ONCOLOGY TO LAY OFF 35% OF STAFF

Jan. 19, 2024

* COMANCHE BIOPHARMA RAISES $75M TO FUND PREECLAMPSIA DRUG TESTING

Jan. 17, 2024

* WOMEN’S HEALTH COMPANIES, BATTLING UNDER-INVESTMENT IN RESEARCH, SEE GROWING
OPPORTUNITY

Jan. 16, 2024

* JPM24: PFIZER’S TOUGH SELL, THE NEXT KARUNA AND BUILDING A BIOTECH PLATFORM

Jan. 9, 2024

* JPM24: NVIDIA’S AI DREAMS, SAREPTA’S ROSY OUTLOOK AND JEFF JONAS’ NEW JOB

Jan. 8, 2024

* YEAR OF BIOTECH LAYOFFS LEAVES INDUSTRY LOOKING FOR SPARK

Jan. 8, 2024

* NOVARTIS DEEPENS TIES WITH VOYAGER VIA $100M GENE THERAPY DEAL

Jan. 2, 2024

* 10 CLINICAL TRIALS TO WATCH IN THE FIRST HALF OF 2024

Jan. 2, 2024

* MERCK GETS FDA DECISION DATE FOR NEW PNEUMOCOCCAL VACCINE

Dec. 19, 2023

* FOUNDATION BEHIND NOVO NORDISK TO INVEST $260M IN VACCINE R&D

Dec. 18, 2023

* VIR TO LAY OFF STAFF, CUT COSTS AMID SETBACKS BUILDING ON COVID SUCCESS

Dec. 14, 2023

* SUPREME COURT TO RULE ON ABORTION PILL ACCESS

Dec. 13, 2023

* ASTRAZENECA TO ACQUIRE VACCINE MAKER ICOSAVAX FOR UP TO $1.1B

Dec. 12, 2023

* SPYRE THERAPEUTICS RAISES $180 MILLION TO ADVANCE ANTI-INFLAMMATORY DRUGS

Dec. 8, 2023

* FUJIFILM TO INVEST $200M IN CELL THERAPY PRODUCTION

Dec. 6, 2023

* PFIZER, AFTER DELAY, COMPLETES ENROLLMENT IN LYME VACCINE TRIAL

Dec. 5, 2023

* CONCENTRA, ON THE HUNT FOR DEALS, BIDS FOR LIANBIO

Dec. 1, 2023

* GILEAD TO LAY OFF STAFF AT CELL THERAPY UNIT KITE

Nov. 29, 2023

* NOVO TO EXPAND FRENCH PLANT IN GLP-1 PRODUCTION PUSH

Nov. 27, 2023

* MERCK TO BUY PRIVATE BIOTECH CARAWAY IN NEUROSCIENCE DEAL

Nov. 21, 2023

* HOMOLOGY ENTERS REVERSE MERGER WITH Q32 BIO

Nov. 16, 2023

* ALKERMES SEPARATES CANCER DRUG BUSINESS AS NEW COMPANY MURAL

Nov. 15, 2023

* FORBION-BACKED BIOTECH RAISES $138M TO DEVELOP ALS DRUG

Nov. 14, 2023

* VALNEVA’S CHIKUNGUNYA VACCINE APPROVED BY FDA

Nov. 10, 2023

* TAKEDA SECURES FDA APPROVAL FOR COLON CANCER DRUG

Nov. 9, 2023

* FLAGSHIP EXPANDS INTO ASIA-PACIFIC WITH NEW SINGAPORE HUB

Nov. 7, 2023

* VENTYX REVISES TYK2 DRUG PLANS AFTER LACKLUSTER STUDY DATA

Nov. 7, 2023

* MODERNA ADJUSTS TO CHANGING OUTLOOK FOR COVID VACCINE DEMAND

Nov. 3, 2023

* SANGAMO TO CUT JOBS AGAIN WITH PLANNED BUSINESS OVERHAUL

Nov. 2, 2023

* PFIZER RSV VACCINE GETS OFF TO FAST START ON MARKET

Oct. 31, 2023

* SANOFI INVESTS IN MEIRAGTX AND ITS GENE-REGULATING TECHNOLOGY

Oct. 30, 2023

* LESSONS FROM A BIOTECH DOWNTURN: FUNDING CHALLENGES, AN IPO DRY SPELL AND
WHAT TO EXPECT IN 2024

Oct. 26, 2023

* SUPPLY SHORTAGE HITS INFANT RSV ANTIBODY BEYFORTUS

Oct. 25, 2023

* ORBIMED RAISES $4.3B IN NEW FUNDS FOR STARTUP INVESTING

Oct. 24, 2023

* PFIZER WINS FDA APPROVAL OF NEW MENINGOCOCCAL VACCINE

Oct. 23, 2023

* CONCENTRA MAKES BID FOR STRUGGLING BIOTECH RAIN

Oct. 16, 2023

* ‘PROJECT NEXTGEN’ PICKS NEW MRNA, INTRANASAL COVID VACCINES FOR FUNDING

Oct. 13, 2023

* RESEARCH GROUP SAYS FDA FOUND NO MISCONDUCT IN PFIZER LYME VACCINE TRIAL IT
HELPED RUN

Oct. 12, 2023

* BAYER OPENS CALIFORNIA PLANT TO MAKE CELL THERAPIES

Oct. 10, 2023

* GSK PARTNERS WITH CHINESE PHARMA TO EXPAND SHINGRIX SALES

Oct. 9, 2023

* MODERNA CLAIMS POSITIVE RESULTS IN EARLY STUDY FOR COMBO COVID, FLU SHOT

Oct. 4, 2023

* LILLY ECZEMA DRUG TURNED BACK BY FDA OVER MANUFACTURING

Oct. 2, 2023

* PTC TO LAY OFF MORE STAFF FOLLOWING DRUG SETBACK IN EUROPE

Sept. 29, 2023

* GRITSTONE WINS ‘PROJECT NEXTGEN’ FUNDING TO RUN HEAD-TO-HEAD COVID VACCINE
STUDY

Sept. 28, 2023

* LATEST TRIAL WIN SUPPORTS EXPANDED USE OF BRISTOL MYERS’ OPDIVO IN LUNG
CANCER

Sept. 22, 2023

* ROCHE’S GENENTECH BETS ON RADIOPHARMACEUTICALS IN PARTNERSHIP WITH PEPTIDREAM

Sept. 20, 2023

* KINNATE LAYS OFF 70% OF STAFF, REORGANIZES PIPELINE

Sept. 19, 2023

* NEW RSV VACCINES CAN BE POWERFUL TOOLS, BUT ROLLOUT POSES TEST

Sept. 18, 2023

* CDC ENDORSES NEW COVID BOOSTERS AS FOCUS TURNS TO ROLLOUT

Sept. 13, 2023

* FDA APPROVES UPDATED COVID BOOSTERS FROM PFIZER, MODERNA

Sept. 11, 2023

* NOVARTIS STOPS WORK ON GENE THERAPY ACQUIRED IN GYROSCOPE DEAL

Sept. 11, 2023

* ASTRAZENECA, SEEKING NEW DRUG TARGETS, TAPS A GENOMICS BIOTECH AND ITS AI
TECHNOLOGY

Sept. 8, 2023

* STARTUP MARIANA RAISES $175M FOR RADIOPHARMACEUTICAL DRUG RESEARCH

Sept. 7, 2023

* MODERNA SAYS UPDATED COVID SHOT LIKELY TO PROTECT AGAINST WORRISOME VARIANT

Sept. 6, 2023

* NESTLE GIVES UP ON PEANUT ALLERGY TREATMENT AFTER SLUGGISH SALES

Sept. 5, 2023

* FIBROGEN’S DUCHENNE DRUG FAILS SECOND TRIAL IN LATEST STUDY SETBACK

Aug. 30, 2023

* MERCK KICKS OFF PHASE 3 TESTS FOR PCSK9 CHOLESTEROL PILL

Aug. 25, 2023

* AGENUS TO LAY OFF 25% OF STAFF, TRIM PIPELINE IN CANCER DRUG PUSH

Aug. 23, 2023

* FDA APPROVES PFIZER’S RSV VACCINE FOR USE IN PREGNANCY

Aug. 21, 2023

* GENESIS RAISES $200 MILLION FOR AI DRUG DISCOVERY RESEARCH

Aug. 21, 2023

* APPEALS COURT RULES TO LIMIT ABORTION PILL ACCESS

Aug. 16, 2023

* FDA DELAYS DECISION ON VALNEVA’S CHIKUNGUNYA VACCINE

Aug. 14, 2023

* FAMILY OF HENRIETTA LACKS SUES ULTRAGENYX OVER USE OF HELA CELL LINE

Aug. 11, 2023

* ASTELLAS TO EXPAND PRESENCE IN MASSACHUSETTS WITH NEW RESEARCH HUB

Aug. 10, 2023

* IKENA ACQUIRES CANCER STARTUP PIONYR AFTER GILEAD PASSES ON BUYOUT

Aug. 7, 2023

* RSV ANTIBODY FROM SANOFI, ASTRAZENECA BACKED BY CDC FOR USE IN INFANTS

Aug. 4, 2023

* MODERNA LOOKS TO NEW COVID BOOSTER, RSV SHOT TO CURB FALLING SALES

Aug. 3, 2023

* KARYOPHARM CUTS STAFF AMID PUSH TO BROADEN USE OF BLOOD CANCER DRUG

Aug. 2, 2023

* FDA DECLINES TO REVIEW BIOHAVEN’S LATEST DRUG IN SETBACK TO PIPELINE

July 27, 2023

* GSK CONFIDENT IN RSV VACCINE LAUNCH, BUT SETS EXPECTATIONS FOR ‘STEADY BUILD’

July 27, 2023

* FIBROGEN CEO RESIGNS AMID LATEST ROUND OF LAYOFFS

July 25, 2023

* BAVARIAN NORDIC TO SCRAP RSV VACCINE AFTER STUDY SETBACK

July 24, 2023

* EMA BACKS PFIZER’S RSV VACCINE FOR USE DURING PREGNANCY

July 21, 2023

* VIR, STRUGGLING TO BUILD ON COVID SUCCESS, SAYS FLU ANTIBODY FAILS KEY STUDY

July 20, 2023

* AMARIN, FIBROGEN LAY OFF STAFF AS BIOTECH COST CUTTING CONTINUES

July 19, 2023

* A CANCER BIOTECH’S COLLAPSE GIVES NEUROGENE A PATH TO WALL STREET

July 18, 2023

* FDA APPROVES NEW RSV DRUG TO PROTECT INFANTS, TODDLERS

July 17, 2023

* NOVARTIS BUYS A PRECLINICAL BIOTECH AND ITS RNA DRUG TECHNOLOGY

July 17, 2023

* RNA EDITING SPECIALIST KORRO TO GO PUBLIC VIA REVERSE MERGER

July 14, 2023

* FIRST NONPRESCRIPTION BIRTH CONTROL PILL APPROVED BY FDA

July 13, 2023

* TAKEDA WITHDRAWS FDA APPROVAL APPLICATION FOR DENGUE VACCINE

July 11, 2023

* SEPTERNA RAISES $150M TO FUEL GPCR DRUG RESEARCH

July 11, 2023

* ASTELLAS BUYS RIGHTS TO 4D MOLECULAR’S TECHNOLOGY IN LATEST GENE THERAPY DEAL

July 10, 2023

* BRII BUYS FURTHER INTO VBI THERAPY, EXPANDING HEPATITIS B PARTNERSHIP

July 6, 2023

* IPSEN GAINS FDA PANEL BACKING FOR BONE DRUG ACQUIRED IN $1.3B BUYOUT

June 29, 2023

* PFIZER’S HEMOPHILIA B GENE THERAPY INCHES CLOSER TO REGULATORY APPROVAL

June 27, 2023

* 5 FDA DECISIONS TO WATCH IN THE THIRD QUARTER

June 26, 2023

* BAVARIAN NORDIC SAYS CHIKUNGUNYA VACCINE SUCCEEDS IN LATE-STAGE STUDY

June 20, 2023

* FDA ADVISERS ENDORSE UPDATING COVID SHOTS TO MATCH CIRCULATING VIRUS STRAIN

June 16, 2023

* ACADIA GIVES ONCE-REJECTED PRADER-WILLI DRUG A SECOND CHANCE

June 14, 2023

* FERRING, WITH MANUFACTURING UPDATE, TAKES A STEP TOWARDS FIRST GENE THERAPY
SALES

June 13, 2023

* NOVO NORDISK TO INVEST OVER $2B IN DRUG INGREDIENT PRODUCTION

June 12, 2023

* FDA ADVISERS BACK RSV ANTIBODY DRUG FOR USE IN INFANTS

June 9, 2023

* FDA STAFF APPEAR SUPPORTIVE OF RSV DRUG FROM ASTRAZENECA, SANOFI

June 6, 2023

* PFIZER SAYS ANTIBIOTIC IS EFFECTIVE AGAINST TOUGH-TO-TREAT INFECTIONS

June 2, 2023

* ASTRAZENECA ABANDONS EXPERIMENTAL BOWEL DISEASE DRUG

June 1, 2023

* PFIZER’S RSV VACCINE WINS FDA APPROVAL IN OLDER ADULTS

May 31, 2023

* BIOHAVEN SENDS LATEST DRUG TO FDA, DESPITE PAST TRIAL SETBACK

May 31, 2023

* AMYLYX’S ALS DRUG COULD FACE REJECTION IN EUROPE

May 30, 2023

* BENEVOLENTAI CFO RESIGNS AS COMPANY LAYS OFF STAFF, RESTRUCTURES

May 25, 2023

* FDA APPROVES NEW ANTIBIOTIC FOR HOSPITAL-ACQUIRED PNEUMONIA

May 24, 2023

* FDA APPROVES KRYSTAL GENE THERAPY FOR RARE WOUND DISORDER

May 22, 2023

* NOVAVAX CUTS WORKFORCE BY 25% AS COVID VACCINE SALES FALL

May 9, 2023

* FORMER RUBIUS, LARONDE CEO CAGNONI TO JOIN INCYTE

May 8, 2023

* CONVERGENT RAISES $90M TO DEVELOP ITS RADIOPHARMACEUTICAL FOR PROSTATE CANCER

May 5, 2023

* VALNEVA, PFIZER PUSH BACK TIMELINE FOR LYME DISEASE VACCINE

May 4, 2023

* FDA APPROVES FIRST RSV VACCINE, CLEARING GSK’S AREXVY FOR OLDER ADULTS

May 3, 2023

* J&J, BUILDING ON CAR-T SUCCESS, STRIKES ANOTHER CELL THERAPY DEAL

May 2, 2023

* FDA CLEARS PFIZER’S PNEUMOCOCCAL VACCINE FOR INFANTS AND CHILDREN

April 28, 2023

* NOVARTIS PLANT CLEARED TO PRODUCE IN-DEMAND CANCER DRUG

April 24, 2023

* SUPREME COURT MAINTAINS ACCESS TO ABORTION PILL, BLOCKING RESTRICTIONS ON ITS
USE

April 21, 2023

* SUPREME COURT DELAYS DECISION IN BATTLE OVER ABORTION PILL

April 19, 2023

* FDA FAVORS SINGLE DOSE OF UPDATED COVID SHOTS IN SHIFT TO SIMPLIFY
VACCINATION

April 18, 2023

* VAXCYTE STRENGTHENS CASE FOR EXPERIMENTAL PNEUMOCOCCAL VACCINE

April 17, 2023

* APPEALS COURT RULES ABORTION DRUG CAN STAY ON MARKET — BUT LIMITS ACCESS

April 13, 2023

* CENTURY THERAPEUTICS CHANGES LEADERSHIP AS CEO STEPS DOWN

April 12, 2023

* BIOTECH FEARS ‘DANGEROUS’ PRECEDENT AS JUDGE CHALLENGES FDA AUTHORITY

April 10, 2023

* FEDERAL JUDGE INVALIDATES FDA APPROVAL OF ABORTION PILL

April 8, 2023

* ABBVIE REMOVES TWO APPROVALS FOR BLOOD CANCER DRUG IMBRUVICA

April 7, 2023

* IN NEJM, FULL PFIZER DATA SHOW RSV VACCINE’S PROTECTION

April 5, 2023

* BIONTECH MOVES INTO ADCS WITH DUALITY DEAL

April 3, 2023

* 5 FDA DECISIONS TO WATCH IN THE SECOND QUARTER

April 3, 2023

* FDA APPROVES NARCAN FOR OVER-THE-COUNTER USE

March 30, 2023

* NOVARTIS TAPS BICYCLE TO DEVELOP RADIOPHARMACEUTICAL DRUGS FOR CANCER

March 28, 2023

* NOVO PARTNERS WITH DEWPOINT TO MINE AN EMERGING FIELD FOR NEW DRUGS

March 22, 2023

* NOVO NORDISK FOLLOWS LILLY IN SHARPLY CUTTING INSULIN PRICES

March 14, 2023

* SANOFI ACQUIRES DIABETES DRUG VIA PROVENTION BUYOUT

March 13, 2023

* SANDOZ, BETTING ON BIOSIMILAR SALES, TO BUILD NEW PRODUCTION PLANT

March 9, 2023

* CONTROVERSIAL DRUG FOR PRETERM BIRTH TO BE WITHDRAWN, MAKER SAYS

March 8, 2023

* FDA DECISION ON PRETERM BIRTH DRUG’S WITHDRAWAL NEARS, PUTTING SPOTLIGHT ON
PATIENTS, AGENCY

March 6, 2023

* NOVARTIS TAKES STEP TOWARD EXPANDING SUPPLY OF IN-DEMAND CANCER DRUG

March 3, 2023

* GSK’S RSV VACCINE WINS FDA PANEL BACKING, MATCHING PFIZER

March 2, 2023

* PFIZER’S RSV VACCINE GETS LUKEWARM BACKING OF FDA ADVISERS

March 1, 2023

* VIATRIS TAPS NEW CEO TO LEAD SECOND PHASE OF BUSINESS REVAMP

Feb. 27, 2023

* MODERNA SHARES SINK AMID COVID FORECASTS, TRIAL NEWS

Feb. 23, 2023

* MERCK’S COVID-19 TREATMENT FALLS SHORT IN PREVENTION STUDY

Feb. 21, 2023

* MODERNA SHARES SINK ON MIXED STUDY RESULTS FOR FLU VACCINE

Feb. 17, 2023

* NEW CANCER CELL THERAPY BIOTECH EMERGES, BACKED BY MD ANDERSON AND REPLAY

Feb. 14, 2023

* FREQUENCY TO CUT JOBS AFTER CLINICAL TRIAL SETBACK

Feb. 13, 2023

* PFIZER BEGINS PLAN TO CHALLENGE SHINGRIX WITH AN MRNA VACCINE

Feb. 10, 2023

* ARROWHEAD CONFIRMS J&J’S PLAN TO DIAL BACK HEPATITIS B DRUG RESEARCH

Feb. 7, 2023

* J&J SAYS DRUG IT ACQUIRED FROM MOMENTA SUCCEEDS IN STUDY OF ULTRA-RARE
CONDITION

Feb. 6, 2023

* COVID-19 VACCINE MAKER MEDICAGO TO CLOSE DOWN

Feb. 3, 2023

* FDA TO CONVENE ADVISERS ON REVIEW OF RSV VACCINES FROM GSK, PFIZER

Feb. 1, 2023

* 3 MORE BIOTECHS ANNOUNCE LAYOFFS AS INDUSTRY COST-CUTTING CONTINUES

Feb. 1, 2023

* MODERNA REPORTS POSITIVE RSV VACCINE RESULTS, PRESSURING PFIZER, GSK

Jan. 18, 2023

* LEAP THERAPEUTICS TO BUY FLAME BIOSCIENCES IN ALL-STOCK DEAL

Jan. 17, 2023

* EMA WEIGHS NEW SAFETY GUIDANCE FOR NOVARTIS’ GENE THERAPY ZOLGENSMA

Jan. 13, 2023

* JPM23: TAKEDA TESTS BRISTOL MYERS, PRIME WEIGHS SPINOFFS AND SANOFI FACES
DOWN A COMPETITOR

Jan. 11, 2023

* NOVAVAX’S ERCK TO DEPART AFTER 12 YEARS AS CEO

Jan. 9, 2023

* 5 FDA DECISIONS TO WATCH IN THE FIRST QUARTER

Jan. 9, 2023

* ENSOMA BUYS A STARTUP TO ADVANCE ‘IN VIVO’ CELL THERAPY WORK

Jan. 6, 2023

* KENVUE, J&J’S CONSUMER HEALTH UNIT, FILES FOR AN IPO IN STEP TOWARD SPLIT

Jan. 5, 2023

* PREVAIL, CAPSIDA PARTNER TO DEVELOP GENE THERAPIES FOR NERVOUS SYSTEM
DISEASES

Jan. 4, 2023

* PFIZER SAYS HEMOPHILIA B GENE THERAPY CONTROLLED BLEEDING IN KEY STUDY

Dec. 29, 2022

* HEARING LOSS BIOTECH OTONOMY PLANS TO DISSOLVE

Dec. 20, 2022

* FERRING WINS FDA APPROVAL FOR BLADDER CANCER GENE THERAPY

Dec. 19, 2022

* SIO GENE THERAPIES TO DISSOLVE AFTER YEARS OF SETBACKS

Dec. 15, 2022

* CYTOKINETICS HEART DRUG VOTED DOWN BY FDA PANEL

Dec. 14, 2022

* BLACK DIAMOND SPINS OUT NEW BIOTECH TO DEVELOP CANCER DRUGS

Dec. 13, 2022

* BIOTECH LAYOFFS CLAIM MORE JOBS AT SENSEI, INSTIL, THERAPEUTICSMD

Dec. 9, 2022

* IMMUNE DRUG DEVELOPER APOGEE EMERGES AS FIRST SPINOUT OF BIOTECH PARAGON

Dec. 7, 2022

* VERVE SHARES SLIDE AFTER COMPANY REVEALS DETAILS ON FDA TRIAL HOLD

Dec. 6, 2022

* THERAPEUTICSMD TO OFFLOAD DRUGS TO AUSTRALIA’S MAYNE AFTER FAILED BUYOUT

Dec. 5, 2022

* J&J’S DUATO TO REPLACE DEPARTING GORSKY AS BOARD CHAIR

Dec. 2, 2022

* ROCHE STUDY FAILURE GIVES ALZHEIMER’S RESEARCHERS NEW CLUES IN DRUG QUEST

Dec. 1, 2022

* SANA RESHUFFLES DRUG PIPELINE, BECOMING LATEST BIOTECH TO CUT STAFF

Nov. 30, 2022

* SPECTRUM TO LAY OFF R&D STAFF AFTER FDA DRUG REJECTION

Nov. 28, 2022

* NOVARTIS, RESEARCH GROUP TO ADVANCE NEW KIND OF MALARIA DRUG INTO LATE-STAGE
TEST

Nov. 23, 2022

* BIOTECH OBSEVA SELLS DRUG RIGHTS TO FORESTALL FUNDING CRUNCH

Nov. 22, 2022

* REPLAY REVEALS SECOND GENE THERAPY SPINOUT, DEBUTING NEW BIOTECH TELARIA

Nov. 21, 2022

* FIRST-OF-ITS-KIND TYPE 1 DIABETES DRUG WINS FDA APPROVAL

Nov. 18, 2022

* PFIZER, BIONTECH START STUDY TESTING NEXT COVID-19 VACCINE

Nov. 17, 2022

* BIOTECHS REVEAL LAYOFFS, RESEARCH REVAMPS IN THIRD QUARTER EARNINGS

Nov. 16, 2022

* TRIAL FAILURES END LATEST HOPE FOR ROCHE’S ALZHEIMER’S DRUG

Nov. 14, 2022

* NOVAVAX DETAILS TRIAL RESULTS FOR OMICRON-TARGETING BOOSTER SHOTS

Nov. 8, 2022

* VIATRIS TO BUY TWO EYE DRUG DEVELOPERS IN DEALS WORTH UP TO $750M

Nov. 7, 2022

* PFIZER, BIONTECH DATA SUPPORT NEW COVID BOOSTER’S ADVANTAGE OVER ORIGINAL
VACCINE

Nov. 4, 2022

* MODERNA CUTS SALES FORECASTS FOR ITS COVID-19 VACCINE

Nov. 3, 2022

* SURFACE ONCOLOGY TO LAY OFF 20% OF STAFF IN RESTRUCTURING

Nov. 2, 2022

* REPLAY LAUNCHES GENE THERAPY SPINOUT EUDORA, PUTTING ‘HUB-AND-SPOKE’ PLANS TO
WORK

Oct. 31, 2022

* GSK SHELVES FILING PLANS FOR ARTHRITIS DRUG AFTER TRIAL RESULTS

Oct. 27, 2022

* ASTELLAS TAKES STAKE IN GENE THERAPY DEVELOPER TAYSHA

Oct. 24, 2022

* ‘I DON’T FEEL SAFE.’ ABORTION BANS ADD NEW UNCERTAINTY TO FERTILITY TREATMENT

Oct. 24, 2022

* PFIZER, BIONTECH SAY UPDATED COVID BOOSTER RAISED OMICRON ANTIBODY LEVELS IN
TRIAL

Oct. 13, 2022

* NIMBUS PARTNERS WITH ELI LILLY ON METABOLIC DISEASE RESEARCH

Oct. 12, 2022

* FDA REJECTS SUPERNUS’ DRUG INFUSION DEVICE FOR PARKINSON’S

Oct. 10, 2022

* BIONTECH TO BUILD AN MRNA HUB IN AUSTRALIA

Oct. 6, 2022

* NOBEL PRIZE IN CHEMISTRY AWARDED TO BIOTECH FOUNDER BERTOZZI, TWO OTHERS

Oct. 5, 2022

* ASTRAZENECA TO ACQUIRE GENE EDITING BIOTECH LOGICBIO

Oct. 3, 2022

* 5 FDA DECISIONS TO WATCH IN THE FOURTH QUARTER

Oct. 3, 2022

* BIOMARIN RESUBMITS ITS HEMOPHILIA GENE THERAPY TO THE FDA

Sept. 30, 2022

* J&J’S CONSUMER HEALTH SPINOUT TO BE NAMED KENVUE

Sept. 28, 2022

* PFIZER, BIONTECH SEEK FDA CLEARANCE FOR UPDATED COVID-19 BOOSTER IN CHILDREN

Sept. 26, 2022

* PFIZER, SANGAMO SET TO RESUME GENE THERAPY STUDY AFTER SAFETY DELAY

Sept. 23, 2022

* J&J OPENS NEW RESEARCH HUB NEAR SAN FRANCISCO

Sept. 20, 2022

* GENFIT, CONTINUING REBUILD, BUYS STARTUP VERSANTIS

Sept. 19, 2022

* ASTRAZENECA CLAIMS POSITIVE RESULTS FOR ITS “ADD-ON” DRUG FOR RARE BLOOD
DISEASE

Sept. 16, 2022

* PFIZER BRINGS MRNA FLU VACCINE INTO PHASE 3 TESTING

Sept. 14, 2022

* BLUEBIRD CFO RESIGNS AHEAD OF GENE THERAPY LAUNCH

Sept. 12, 2022

* BACKED BY BRISTOL MYERS, ARSENALBIO RAISES $220M FOR ITS CELL THERAPY
RESEARCH

Sept. 7, 2022

* CDC BACKS UPDATED COVID SHOTS FROM PFIZER, MODERNA

Sept. 2, 2022

* BIOTECH STARTUP OCEAN PIVOTS FROM IPO TO SPAC MERGER

Aug. 31, 2022

* FDA CLEARS UPDATED COVID-19 BOOSTERS FROM PFIZER, MODERNA

Aug. 31, 2022

* PFIZER FOLLOWS GSK WITH POSITIVE PHASE 3 RESULTS FOR RSV VACCINE

Aug. 25, 2022

* MERCK BACKS RADIOPHARMACEUTICAL STARTUP AKTIS, JOINING OTHER HIGH-PROFILE
BACKERS

Aug. 25, 2022

* PFIZER’S NEW PNEUMOCOCCAL VACCINE MEETS STUDY GOAL IN CHILDREN

Aug. 12, 2022

* SHIFTING FOCUS, PROQR TO SEEK PARTNERS FOR STALLED EYE DRUGS

Aug. 11, 2022

* PFIZER, VALNEVA TAKE NEXT STEP WITH LYME DISEASE SHOT, STARTING LARGE TRIAL

Aug. 9, 2022

* LILLY CRITICIZES INDIANA ABORTION LAW, INDICATING IT MAY LOOK ELSEWHERE TO
HIRE

Aug. 8, 2022

* PFIZER BUYS SICKLE CELL DRUGMAKER GLOBAL BLOOD FOR $5.4B

Aug. 8, 2022

* ELEVATEBIO, BOSTON CHILDREN’S LAUNCH STARTUP TO TEST NEW APPROACH TO
‘OFF-THE-SHELF’ CELL THERAPY

Aug. 4, 2022

* ABCELLERA INKS ANOTHER VENTURE PARTNERSHIP, THIS TIME WITH ATLAS

Aug. 3, 2022

* HOW BELITE BIO, A SMALL, UNDER-THE-RADAR DRUGMAKER, EMERGED AS ONE OF
BIOTECH’S BEST PERFORMING IPOS

Aug. 2, 2022

* IPSEN, CONTINUING ONCOLOGY PUSH, PAYS A STARTUP $45M FOR TWO CANCER DRUGS

Aug. 1, 2022

* US SECURES UPDATED COVID BOOSTERS IN $1.7B DEAL WITH MODERNA

July 29, 2022

* VERTEX TO MOVE NON-OPIOID PAINKILLER INTO LATE-STAGE TESTS AFTER FDA
AGREEMENT

July 22, 2022

* CDC BACKS NOVAVAX’S PROTEIN-BASED VACCINE FOR COVID-19

July 20, 2022

* BIOTECH DOWNTURN HITS ANOTHER STARTUP AS PACT PHARMA TO LAY OFF NEARLY 100
EMPLOYEES

July 19, 2022

* NESTLÉ EXPANDS MICROBIOME DRUG WORK WITH BIOTECH DEAL

July 18, 2022

* CYTOMX LAYS OFF STAFF, JOINING GROWING LIST OF BIOTECHS RESTRUCTURING

July 14, 2022

* THERAPEUTICSMD BUYOUT UNRAVELS AS SHAREHOLDERS BALK

July 13, 2022

* BAIN CAPITAL BACKS NEW BIOTECH STARTUP DEVELOPING ORAL ASTHMA DRUG

July 12, 2022

* MODERNA FOUNDER LAUNCHES APRIORI WITH $50M TO STAY AHEAD OF VIRUS VARIANTS

July 11, 2022

* ADC THERAPEUTICS CUTS DEAL WITH SOBI TO BROADEN REACH OF CANCER DRUG

July 8, 2022

* TWO CANCER BIOTECHS MERGE, RAISE CASH AS SECTOR-WIDE DOWNTURN CONTINUES

July 5, 2022

* PFIZER SEEKS FULL FDA APPROVAL OF PAXLOVID AS QUESTIONS ABOUT ITS BENEFITS
GROW

June 30, 2022

* BAYER, AMGEN BACK RECODE’S PLAN TO BROADEN GENETIC MEDICINE’S REACH

June 29, 2022

* NOVARTIS TO INVEST $250M IN TROPICAL DISEASE DRUG RESEARCH

June 22, 2022

* A BIOTECH STARTUP LAUNCHES WITH $38M TO DEVELOP A CYSTIC FIBROSIS GENE
THERAPY

June 21, 2022

* BOEHRINGER EXTENDS CANCER DEALMAKING WITH RIGHT TO BUY BIOTECH PARTNER

June 16, 2022

* FORBION RAISES $500M TO BACK GROWING BIOTECHS AMID INDUSTRY SLUMP

June 10, 2022

* PFIZER TO INVEST $120M, ADD JOBS IN PAXLOVID PRODUCTION PUSH

June 7, 2022

* BIOTECH ATHERSYS TO LAY OFF 70% OF STAFF IN COST-CUTTING EFFORT

June 6, 2022

REACH A TARGETED AUDIENCE

DiveWire guarantees visibility for your news announcements through instant
distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers
for 21 days.

Post a press release ➔

Access now➔
Roche
Trendline

THE STATE OF BIOSIMILARS IN 2024

The arrival of lookalike competition to AbbVie’s Humira in the U.S. presents an
opportunity, and a test, for the cost-saving potential of biosimilars.

GET THE FREE NEWSLETTER

Subscribe to BioPharma Dive for top news, trends & analysis

Email:
* Select Newsletter: Daily Dive M-F
* Select Newsletter: Commercialization Weekly Every Wednesday
* Select Newsletter: Gene Therapy Weekly Every Thursday
* Select Newsletter: Emerging Biotech Weekly Every Tuesday
* Select user consent: By signing up to receive our newsletter, you agree to
our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

www.biopharmadive.com Open in urlscan Pro 2606:4700:4400::ac40:91e0 Public Scan

Form analysis 6 forms found in the DOM

Name: signup-inter-form — POST /signup/

GET /search/

.

Name: signup — POST /signup/

GET /search/

Name: signup — POST /signup/

Text Content

www.biopharmadive.com Open in urlscan Pro
2606:4700:4400::ac40:91e0 Public Scan

Form analysis
6 forms found in the DOM